Development and application of amphotericin B immunoassay for pharmacokinetic studies and therapeutic drug monitoring in critically ill patients
- 4 June 2022
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 218, 114875
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- New facets of antifungal therapyVirulence, 2016
- Immunochemical detection of apramycin as a contaminant in tissues of edible animalsFood Control, 2013
- Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complexDiagnostic Microbiology and Infectious Disease, 2013
- Hapten modification approach for switching immunoassay specificity from selective to genericJournal of Immunological Methods, 2013
- Amphotericin primarily kills yeast by simply binding ergosterolProceedings of the National Academy of Sciences, 2012
- Conjugation of amino-containing drugs to polysaccharides by tosylation: amphotericin B–arabinogalactan conjugatesBiomaterials, 2004
- Quantitation of Free and Total Amphotericin B in Human Biologic Matrices by a Liquid Chromatography Tandem Mass Spectrometric MethodTherapeutic Drug Monitoring, 2001
- A Sensitive Amphotericin B Immunoassay for Pharmacokinetic and Distribution StudiesAntimicrobial Agents and Chemotherapy, 2000
- Antibodies to nystatin demonstrate polyene sterol specificity and allow immunolabeling of sterols in Saccharomyces cerevisiaeAntimicrobial Agents and Chemotherapy, 1989
- Induction of amphotericin B-specific antibodies for use in immunoassaysAntimicrobial Agents and Chemotherapy, 1984